How Is Chronic Lymphocytic Leukemia Treated?

This content has been reviewed and approved by

Hagop M. Kantarjian, MD
Chairman & Professor, Leukemia Department
MD Anderson Cancer Center
University of Texas
 

In the early stages, chronic lymphocytic leukemia (CLL) may not need treatment and you may be only observed. Many patients may live their normal life span not needing any treatment. Treatment is generally advised in patients with advanced CLL (Rai stage III-IV), if there is bulky disease (lymph nodes, liver spleen), if they have complications of CLL (infections, immune problems), or if they have significant symptoms caused by CLL, such as fatigue, sweats, fever, weight loss, severe skin itching/lesions, or others.

Specific treatment for CLL will be determined by your physician based on:

  • Your age, overall health, and medical history
  • Extent of the disease
  • Stage of the disease
  • Your tolerance for specific medications, procedures, or therapies
  • Expectations for the course of the disease
  • Your opinion or preference
Treatment may include:
  • Chemotherapy
  • Monoclonal antibodies (Rituxan® [rituximab] or Campath® [alemtuzumab]
  • Treatment for complications, such as infection or anemia
  • Bone marrow transplantation
  • Splenectomy - surgery to remove the spleen
  • Radiation therapy
This content was last reviewed August 15, 2010 by Dr. Reshma L. Mahtani.
Latest Chronic Lymphocytic Leukemia News
Leukemia patients at greatest risk of listeriosis

December 23, 2011 — NEW YORK (Reuters Health) - People with certain conditions, including leukemia, other cancers and pregnancy, are at the greatest risk of getting sick from the food-borne bacterium Listeria, French researchers report in a new study.

Gene therapy shown to destroy leukemia tumors

August 11, 2011 — LOS ANGELES (Reuters) - Scientists for the first time have used gene therapy to successfully destroy cancer tumors in patients with advanced disease -- a goal that has taken 20 years to achieve.

UK's NICE backs lymphoma drug maintenance therapy

May 24, 2011 — LONDON (Reuters) - Roche's cancer drug MabThera has been recommended for use on Britain's state health service as a maintenance therapy for patients with follicular non-Hodgkin's lymphoma, expanding the market for the medicine.

Select news items provided by Reuters Health